TUMOR MUTATIONAL LOAD PREDICTS SURVIVAL AFTER IMMUNOTHERAPY ACROSS MULTIPLE CANCER TYPES.

This analysis of clinical and genomic data from 1662 patients with advanced cancer who were treated with immune checkpoint inhibitors (ICI) and 5371 patients who did not receive ICI was designed to investigate if tumor mutational burden (TMB) predicts clinical response to ICI. Higher TMB was associated with improved overall survival among all patients; however, the TMB cut-points associated with these improvements varied among different cancer types.

These findings support an association between TMB and improved survival among cancer patients treated with ICI.

https://www.nature.com/articles/s41588-018-0312-8